In a considerable development, biotech player Noxopharm (ASX:NOX) has released details of the radiographic review of its DARRT-1 clinical study. The Company reported that the review demonstrates a significant benefit from a combination of low-dose radiotherapy and Veyonda®.
Additionally, the Company highlighted:
- Review providing further evidence of Veyonda®’s anti-cancer effect in patients with end-stage prostate cancer.
- 4/15 patients witnessed an abscopal response following DARRT, which is a remarkable result.
- In Company’s knowledge, this is first time that anyone has been able to attain a meaningful abscopal response rate in prostate cancer.
Post the key update, NOX stock inched higher by ~2.4 per cent, trading at $0.210 as at 12:07 PM AEST on 30th April 2020.
Disclaimer
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.
